Suppr超能文献

使ARID1A肿瘤抑制因子失活可增强端粒酶逆转录酶(TERT)转录并维持癌细胞中的端粒长度。

Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells.

作者信息

Suryo Rahmanto Yohan, Jung Jin-Gyoung, Wu Ren-Chin, Kobayashi Yusuke, Heaphy Christopher M, Meeker Alan K, Wang Tian-Li, Shih Ie-Ming

机构信息

From the Department of Pathology, the Sidney Kimmel Comprehensive Cancer Center, and

From the Department of Pathology, the Sidney Kimmel Comprehensive Cancer Center, and.

出版信息

J Biol Chem. 2016 Apr 29;291(18):9690-9. doi: 10.1074/jbc.M115.707612. Epub 2016 Mar 7.

Abstract

ARID1A is a tumor suppressor gene that belongs to the switch/sucrose non-fermentable chromatin remodeling gene family. It is mutated in many types of human cancer with the highest frequency in endometrium-related ovarian and uterine neoplasms including ovarian clear cell, ovarian endometrioid, and uterine endometrioid carcinomas. We have previously reported that mutations in the promoter of human telomerase reverse transcriptase (TERT) rarely co-occur with the loss of ARID1A protein expression, suggesting a potential role of ARID1A in telomere biology. In this study, we demonstrate that ARID1A negatively regulates TERT transcriptional regulation and activity via binding to the regulatory element of TERT and promotes a repressive histone mode. Induction of ARID1A expression was associated with increased occupancy of SIN3A and H3K9me3, known transcription repressor and histone repressor marks, respectively. Thus, loss of ARID1A protein expression caused by inactivating mutations reactivates TERT transcriptional activity and confers a survival advantage of tumor cells by maintaining their telomeres.

摘要

ARID1A是一种肿瘤抑制基因,属于SWI/SNF染色质重塑基因家族。它在多种人类癌症中发生突变,在与子宫内膜相关的卵巢和子宫肿瘤中频率最高,包括卵巢透明细胞癌、卵巢子宫内膜样癌和子宫子宫内膜样癌。我们之前报道过,人类端粒酶逆转录酶(TERT)启动子突变很少与ARID1A蛋白表达缺失同时出现,提示ARID1A在端粒生物学中可能发挥作用。在本研究中,我们证明ARID1A通过与TERT的调控元件结合来负向调节TERT的转录调控和活性,并促进一种抑制性组蛋白模式。ARID1A表达的诱导与SIN3A和H3K9me3的占据增加相关,SIN3A和H3K9me3分别是已知的转录抑制因子和组蛋白抑制标记。因此,由失活突变导致的ARID1A蛋白表达缺失会重新激活TERT转录活性,并通过维持端粒赋予肿瘤细胞生存优势。

相似文献

1
Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells.
J Biol Chem. 2016 Apr 29;291(18):9690-9. doi: 10.1074/jbc.M115.707612. Epub 2016 Mar 7.
3
ARID1A-SIN3A drives retinoic acid-induced neuroblastoma differentiation by transcriptional repression of TERT.
Mol Carcinog. 2019 Nov;58(11):1998-2007. doi: 10.1002/mc.23091. Epub 2019 Jul 31.
7
ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.
Cancer Res. 2011 Nov 1;71(21):6718-27. doi: 10.1158/0008-5472.CAN-11-1562. Epub 2011 Sep 7.
8
[Tumor suppressor role of chromatin-remodeling factor ARID1A].
Yi Chuan. 2013 Mar;35(3):255-61. doi: 10.3724/sp.j.1005.2013.00255.
9
ARID1A-mutated ovarian cancers depend on HDAC6 activity.
Nat Cell Biol. 2017 Aug;19(8):962-973. doi: 10.1038/ncb3582. Epub 2017 Jul 24.
10
Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response.
J Biomed Sci. 2022 Sep 19;29(1):71. doi: 10.1186/s12929-022-00856-5.

引用本文的文献

1
Melatonin and Breast Cancer: A Review Article.
Chonnam Med J. 2025 May;61(2):63-74. doi: 10.4068/cmj.2025.61.2.63. Epub 2025 May 23.
3
The Role of the AT-Rich Interaction Domain 1A Gene () in Human Carcinogenesis.
Genes (Basel). 2023 Dec 19;15(1):5. doi: 10.3390/genes15010005.
4
ARID1A loss activates MAPK signaling via DUSP4 downregulation.
J Biomed Sci. 2023 Dec 9;30(1):94. doi: 10.1186/s12929-023-00985-5.
6
Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors.
Cancer Res. 2023 Aug 15;83(16):2750-2762. doi: 10.1158/0008-5472.CAN-22-3646.
8
Prognostic Significance of ARID1A Expression Patterns Varies with Molecular Subtype in Advanced Gastric Cancer.
Gut Liver. 2023 Sep 15;17(5):753-765. doi: 10.5009/gnl220342. Epub 2023 Feb 15.
9
The Emerging Role of Chromatin Remodeling Complexes in Ovarian Cancer.
Int J Mol Sci. 2022 Nov 8;23(22):13670. doi: 10.3390/ijms232213670.
10
Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response.
J Biomed Sci. 2022 Sep 19;29(1):71. doi: 10.1186/s12929-022-00856-5.

本文引用的文献

1
Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers.
Genes Dev. 2015 Nov 1;29(21):2219-24. doi: 10.1101/gad.269498.115. Epub 2015 Oct 29.
3
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.
Cancer Discov. 2015 Jul;5(7):752-67. doi: 10.1158/2159-8290.CD-14-0849. Epub 2015 Jun 11.
4
Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer.
Science. 2015 May 29;348(6238):1036-9. doi: 10.1126/science.aab0015. Epub 2015 May 14.
5
Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity.
J Clin Invest. 2015 May;125(5):2109-22. doi: 10.1172/JCI79134. Epub 2015 Apr 20.
6
Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.
Science. 2015 Feb 27;347(6225):1006-10. doi: 10.1126/science.1260200. Epub 2015 Feb 5.
9
Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis.
J Natl Cancer Inst. 2014 Jun 4;106(7). doi: 10.1093/jnci/dju146. Print 2014 Jul.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验